| Image |
|
||||||||||||||
| Caption | H&E-stained cross-sections of the skin and ears. A) Normal skin at 10 weeks of age from Supv3l1tm2Jkl/Supv3l1+ Tg(Mx1-cre)1Cgn/0 (Mx1-Cre Supv3L1tm2Jkl/+) mouse. Ad, adipose layer; Der, dermis; Eder, epidermis; SC, subcutaneous muscle fibers. B) Skin from an age-matched Supv3l1tm2Jkl/Supv3l1tm2Jkl Tg(Mx1-cre)1Cgn/0 (Mx1-Cre Supv3L1tm2Jkl/tm2Jkl) animal. HC, hyperkeratosis. Note the thickened epidermis, severe hyperkeratosis, dystrophic dermis, lack of sebaceous glands, and almost total absence of adipose and muscle layers. C) Higher-power magnification of the skin from an Supv3l1tm2Jkl/Supv3l1tm2Jkl Tg(Mx1-cre)1Cgn/0 (Mx1-Cre Supv3L1tm2Jkl/tm2Jkl) animal showing parakeratosis (arrow) and scaling. D) Cross-section of a normal ear of an Supv3l1tm2Jkl/Supv3l1+ Tg(Mx1-cre)1Cgn/0 (Mx1-Cre Supv3L1tm2Jkl/+) animal at 10 weeks of age. E) Cross-section of an ear of an age-matched Supv3l1tm2Jkl/Supv3l1tm2Jkl Tg(Mx1-cre)1Cgn/0 (Mx1-Cre Supv3L1tm2Jkl/tm2Jkl) animal showing disfigured morphology, thickened epidermis, hyperkeratosis, and neutrophilic microabscesses (arrowhead). F) Another Supv3l1tm2Jkl/Supv3l1tm2Jkl Tg(Mx1-cre)1Cgn/0 (Mx1-Cre Supv3L1tm2Jkl/tm2Jkl) cross-section showing an hyperkeratotic area with absent epidermal cells (arrowhead). G) H&E-stained skin section of an Supv3l1tm2Jkl/Supv3l1tm2Jkl Tg(CAG-cre/Esr1*)5Amc/0 (Actb-Esr1/Cre Supv3L1tm2Jkl/tm2Jkl) animal at the age of 12 weeks. H) Dorsal skin from an Supv3l1tm2Jkl/Supv3l1tm2Jkl Tg(CAG-cre/Esr1*)5Amc/0 (Actb-Esr1/Cre Supv3L1tm2Jkl/tm2Jkl) animal injected subcutaneously with tamoxifen at the age of 25 days. Note the absence of adipose tissue, paucity of subcutaneous muscle, dilated blood vessels, and mild hyperkeratosis. I) Skin from the control animal Supv3l1tm2Jkl/Supv3l1+ Tg(CAG-cre/Esr1*)5Amc/0 (Actb-Esr1/Cre Supv3L1tm2Jkl/+) topically treated with 4-hydroxy tamoxifen. J) A skin sample from an Supv3l1tm2Jkl/Supv3l1tm2Jkl Tg(CAG-cre/Esr1*)5Amc/0 (Actb-Esr1/Cre Supv3L1tm2Jkl/tm2Jkl) animal after topical 4-hydroxy tamoxifen treatment. Note hyperkeratotic and parakeratotic changes along with a significantly thickened epidermal layer of cells. Dilated blood vessels in the dermal layer are marked with asterisks. K) Ear cross-section of a control Supv3l1tm2.1Jkl/Supv3l1+ Tg(KRT14-cre/ERT)20Efu/0 (KRT14-Cre/Esr1 Supv3L1tm3Jkl/+) mouse after subcutaneous administration of tamoxifen. Biopsy was taken 4 weeks after subcutaneous administration was completed. L) Ear cross-section of a Supv3l1tm2.1Jkl/Supv3l1tm2.2Jkl Tg(KRT14-cre/ERT)20Efu/0 (KRT14-Cre/Esr1 Supv3L1tm3Jkl/tm4Jkl) littermate of the same sex and age after subcutaneous administration of tamoxifen. Note atrophy of hair follicles, sweat glands, thickening of epidermis, hyperkeratosis, dilation of blood vessels, and infiltrative changes. | ||||||||||||||
| Copyright | This image is from Paul E, Mamm Genome 2009 Feb;20(2):92-108 and is displayed with the permission of Springer Science + Business Media, Inc., New York who owns the copyright. J:144991 | ||||||||||||||
|
Associated Alleles |
|
||||||||||||||
|
Associated Genotypes |
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 04/23/2024 MGI 6.23 |
|
|
|
||
Analysis Tools